InSite Vision is building a rich product pipeline of innovative ophthalmic products, utilizing novel agents and a powerful drug delivery platform.  

Our lead product, AzaSite^® (azithromycin ophthalmic solution) 1%, is an ocular anti-infective product that contains the drug azithromycin. AzaSite, has been approved by the U.S. Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis. AzaSite is formulated with InSite Vision’s proprietary DuraSite^® technology platform.  Another late-stage product candidate formulated with DuraSite is ISV-502 (AzaSite Plus), currently in Phase 3 clinical trials. ISV-502 is a topical combination antibiotic/corticosteroid product in development for infection and inflammation of the eyelids (blepharitis), a condition with unmet medical need and lack of approved treatment options.  We are also leveraging our DuraSite drug delivery vehicle for new products.

The AzaSite family currently includes AzaSite^®, AzaSite Plus^™, and AzaSite Xtra^™ —all of which have been formulated with the DuraSite^® technology platform.

• More about AzaSite (azithromycin ophthalmic solution) 1%
• More about  product candidates in development

 

AzaSite^{® 1,2}

Macrolide for the treatment of bacterial conjunctivitis

^{1, 2}

Besivance

Fluoroquinolone for the treatment of bacterial conjunctivitis

AzaSite Plus^™(ISV-502)

For the treatment of Blepharitis

ISV-305

For the treatment of non-bacterial Blepharitis

ISV-303

For the treatment of pain & inflammation in Cataract Surgery

ISV-101

For the treatment of Dry Eye
*(Under IND filing)

ISV-405*

For the treatment of Ocular Infection
* For ex-U.S. markets only

ISV-102

Adjunct therapy for refractive surgeries

ISV-620

Ocular cosmetic enhancement product

ISV-215

For the treatment of high intraocular pressure (Glaucoma prevention)

1. The U.S. Food & Drug Administration (FDA) has approved InSite Vision’s New Drug Application (NDA) for AzaSite (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis.
2. Inspire Pharmaceuticals (NASDAQ:ISPH) has the responsibility to commercialize AzaSite in the U.S. and Canada in accordance with a completed license agreement. Ongoing activities are focused on licensing AzaSite in markets outside of the U.S. and Canada.